HTA and reimbursement

College voor zorgverzekeringen (CVZ – Netherlands)

  • Cost-effectiveness assessment for drug to be listed on the hospital ‘expensive drug list’
  • Cost-effectiveness assessment for an orphan drug
  • Diabetes (type 1)
  • Diaper dermatitis complicated by candidiasis in infants
  • Heart failure
  • Herpes zoster vaccine
  • HPV vaccine
  • Metabolic syndrome
  • Metastatic soft-tissue sarcoma

Other HTA and reimbursement

  • All Wales Medicines Strategy Group – breakthrough cancer pain
  • All Wales Medicines Strategy Group – infertility
  • All Wales Medicines Strategy Group – iron overload
  • Joint Committee on Vaccination and Immunisation – HPV (UK)
  • Reimbursement authorities – heart failure (Belgium)
  • EU market access training workshop

Scottish Medicines Consortium (SMC – UK)

  • Anthracycline extravasation
  • Breakthrough cancer pain
  • Breast cancer
  • Diabetes (type 2)
  • Epilepsy
  • Gastric cancer
  • Head and neck cancer
  • Hepatitis B
  • HIV
  • Homocystinuria
  • Infertility
  • Iron overload
  • Kidney failure
  • Lung cancer (non-small cell)
  • Parkinson’s disease
  • Psoriatic arthritis
  • Secondary hyperparathyroidism in end stage renal disease
  • Ulcerative colitis